Supriya Lifescience Limited

NSE SUPRIYA.NS

Supriya Lifescience Limited Gross Profit Margin for the year ending March 31, 2024: 36.96%

Supriya Lifescience Limited Gross Profit Margin is 36.96% for the year ending March 31, 2024, a -39.18% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Supriya Lifescience Limited Gross Profit Margin for the year ending March 31, 2023 was 60.77%, a 9.03% change year over year.
Supriya Lifescience Limited Gross Profit Margin for the year ending March 31, 2022 was 55.74%, a -8.29% change year over year.
Supriya Lifescience Limited Gross Profit Margin for the year ending March 31, 2021 was 60.77%, a 27.20% change year over year.
Supriya Lifescience Limited Gross Profit Margin for the year ending March 31, 2020 was 47.78%, a 27.25% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NSE: SUPRIYA.NS

Supriya Lifescience Limited

CEO	Dr. Satish Waman Wagh
IPO Date	Dec. 28, 2021
Location	India
Headquarters	207/208 Udyog Bhavan
Employees	448
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.

Key trends

Past 5 years